peppersite
Peptide

Kisspeptin-10

Kisspeptin-10 is the short ten-amino-acid tail end of the full kisspeptin protein, a brain signal that sits near the top of the reproductive hormone chain. It has been studied in small human research on fertility, IVF egg maturation and low sexual desire.

Researched for
Recovery

At a glance

Type
Peptide
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
100 mcg per Peptide Dosing Protocols. All 2 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 100 mcg, the figure Peptide Dosing Protocols reports for Kisspeptin-10. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Kisspeptin-10 or for anything else, and nothing below has been checked against the study it came from.

9.6 nmol/kg SC (IVF trigger); 1 nmol/kg IV (diagnostic challenge)
Frequency
Single dose (IVF trigger); single dose (diagnostic)Single administration per IVF · Repeatable
Route
subcutaneous
Reported by
Peptide Protocol Wiki
Standard: 100-200 mcg · Low: 50-100 mcg
Frequency
Once daily SC8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments Insulin Syringes (U-100, 0.
Route
Subcutaneous (SC)
Reported by
Peptide Dosing Protocols
What it saysHalf-life: about 4 minutes. The standard dosing for Kisspeptin-10 is 100-200 mcg once daily.
Reconstitution, as reported
  • Sterile water
  • Reconstitute with bacteriostatic water (BAC water) before drawing any dose.
Not yet audited

We have not published an audit on Kisspeptin-10. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

The brain releases kisspeptin, which switches on GnRH, which in turn tells the pituitary gland to release LH and FSH. In men LH prompts the testes to make testosterone, and in women LH and FSH help control ovulation and follicle growth. Researchers link this to the GPR54 receptor, also called KISS1R, and note that kisspeptin works upstream rather than replacing testosterone, so it is unlikely to help if the pituitary or the gonads cannot respond. Kisspeptin-10 acts and clears fast, with a blood half-life of about 4 minutes after injection into a vein, and continuous exposure can make the signal fade, which is called desensitisation. There is no completed Phase 3 trial, no FDA-approved kisspeptin product and no strong long-term safety dataset.

Reported side effects

Seen in studies: in published short-term human studies, kisspeptin-10 and kisspeptin-54 were generally well tolerated. Studies in low sexual desire reported no treatment-related serious adverse events, and IVF trigger studies reported minor events with no severe drug-related events clearly tied to kisspeptin-54. Reported effects include mild flushing or warmth soon after dosing, mild injection-site redness or irritation, short-lived headache, brief mild nausea, and a short rise in LH and FSH that usually falls back toward baseline.

Not ruled out: the signal can fade with repeated or continuous exposure, normal GnRH pulse timing could be disrupted, animal data raise a possible heart and blood-vessel concern whose human relevance is unclear, and long-term effects on hormone-sensitive tissues are unknown. No kisspeptin product is FDA-approved, and FDA reviewers flagged limited public data on kisspeptin-10 impurities. In October 2024 an FDA advisory committee voted against adding kisspeptin-10 to the 503A Bulks List, citing limited safety and effectiveness data, no approved product anywhere, signal fade with chronic dosing and concerning animal findings.

Who should avoid it

People who are pregnant or breastfeeding: kisspeptin is tied to pregnancy and reproductive cycling, and there is no good safety data for these groups.

People with hormone-sensitive cancers: kisspeptin affects sex-hormone signalling, which matters with a history of breast, ovarian or prostate cancer.

People in fertility treatment outside a clinical trial: copying an IVF trigger protocol without clinical monitoring skips the timing, lab work and ultrasound checks the protocol depends on.

People with primary hypogonadism: the problem lies in the testes or ovaries, and kisspeptin works further upstream, so it may not help if the gonads cannot respond.

People with pituitary disease: kisspeptin needs a working pituitary gland to raise LH and FSH.

Children and teenagers: kisspeptin is part of puberty timing.

People with heart or blood-vessel concerns: FDA reviewers flagged animal data that may matter for heart and vascular risk, though human relevance is still unclear.

Common questions

What is kisspeptin?

It is a signalling peptide that helps start the reproductive hormone pathway. It acts on the GPR54 receptor, also called KISS1R, switching on GnRH so the pituitary releases LH and FSH.

What kisspeptin dosage appears in research protocols?

Reported amounts and schedules for Kisspeptin-10 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What is the difference between kisspeptin-10 and kisspeptin-54?

They are not interchangeable, and they differ mainly in how long they last. Kisspeptin-10 has a half-life of about 4 minutes after injection into a vein, while kisspeptin-54 lasts about 28 minutes after injection under the skin, with its peak LH response around 5 hours.

How is kisspeptin reconstituted?

Sources describe it shipping as a freeze-dried powder, with bacteriostatic water added and the vial swirled gently until the liquid is clear.

Open the reconstitution calculator →

What cycle length do kisspeptin protocols describe?

Research-context sources usually describe 2 to 6 weeks on with 2 to 4 weeks off. The stated reason for breaks is desensitisation, where continuous exposure makes the hormone signal fade.

Is kisspeptin FDA-approved?

No. As of June 2026 no kisspeptin product is FDA-approved anywhere in the world, and in October 2024 an FDA advisory committee voted against adding kisspeptin-10 to the 503A Bulks List.

What are the main kisspeptin side effects?

Reported effects in short-term human studies include mild flushing, headache, brief nausea and minor injection-site irritation. Longer-term risks are not characterised, and signal fade with repeated dosing is a known limitation.

Can kisspeptin be used as TRT or for post-cycle therapy?

Kisspeptin is not testosterone replacement. It may raise testosterone indirectly if LH rises and the testes respond, but that is not the same thing, and human evidence for post-cycle therapy or fertility restart is still limited.

Sources

  1. 01Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation (2014)
  2. 02Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF Therapy. Journal of Clinical Endocrinology & Metabolism (2015)
  3. 03Comninos AN, Demetriou L, Wall MB, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2022)
  4. 04Thurston L, Hunjan T, Ertl N, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2023)
  5. 05George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology & Metabolism (2011)
  6. 06Narayanaswamy S, Prague JK, Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction (2015)
  7. 07Abbara A, Eng PC, Phylactou M, et al. Kisspeptin: a novel physiological trigger for oocyte maturation in IVF treatment (Lancet 2014 trial). The Lancet (2014)
  8. 08Trevisan CM, Montagna E, de Oliveira R, et al. Role of Kisspeptin on Hypothalamic-Pituitary-Gonadal Pathology and Its Effect on Reproduction. PMC review (2021)
  9. 09Plant TM The neurobiological mechanism underlying hypothalamic GnRH pulse generation: the role of kisspeptin neurons in the arcuate nucleus. Journal of Endocrinology (2019)
  10. 10Hu KL, Chang HM, Zhao HC, et al. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Frontiers in Endocrinology (2022)
  11. 11Abbara A, Jayasena CN, Comninos AN, et al. Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment. Frontiers in Endocrinology (2022)
  12. 12U.S. Food and Drug Administration FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — Kisspeptin-10 (review against inclusion on 503A Bulks List). FDA (2024)
  13. 13U.S. Food and Drug Administration Summary Minutes, October 29, 2024 PCAC Meeting (kisspeptin-10 vote). FDA (2024)
  14. 14Skorupskaite K, George JT, Anderson RA The kisspeptin-GnRH pathway in human reproductive health and disease. Journal of Endocrinology (review) (2016)
  15. 15George JT, Veldhuis JD, Roseweir AK, et al. Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels. Clinical Endocrinology (2017)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things